cake collapse in lypholisation

Why does freeze-dried cake collapse?

October 15, 2026

What lyophilisation critical temperatures do you need to measure before cycle design?

This guide is written for formulation scientists, process development scientists, and analytical scientists involved in characterising a lyophilised formulation. It is also relevant to project managers and regulatory affairs professionals who receive characterisation data and need to understand what it means for cycle design.

It covers the three critical temperatures that govern freeze-drying process design - Tc, Tg', and Te - what each one means, how each is measured, and how the measurements are used. It is a reference document, not a protocol.

Three temperatures govern how a formulation behaves during freeze-drying. The collapse temperature (Tc) is the primary design parameter for primary drying - it defines the upper limit that product temperature must not exceed. The glass transition temperature of the maximally freeze-concentrated amorphous phase (Tg') correlates with Tc and cross-checks it from a different measurement principle. The eutectic temperature (Te) applies only where crystallising excipients are present and defines the temperature below which crystallisation is complete. All three must be measured for the actual formulation at the target concentration. Published values for individual excipients do not account for the combined mixture and cannot substitute for measurement.

What are Tc, Tg’, and Te?

Answer

Tc is the collapse temperature – the temperature above which the frozen amorphous matrix loses rigidity during primary drying, causing the pore structure of the cake to deform irreversibly. It is the upper limit for product temperature throughout primary drying.

Tg’ is the glass transition temperature of the maximally freeze-concentrated amorphous phase – the temperature at which the amorphous fraction of a frozen formulation transitions from a glassy, rigid state to a rubbery, viscous one. It correlates closely with Tc and is typically 2-5°C below it. A formulation held above Tg’ during primary drying will tend towards collapse as the amorphous matrix softens.

Te is the eutectic temperature – relevant only to formulations containing crystallising components such as mannitol, glycine, or inorganic salts. It is the temperature at which those components exist at the boundary between solid and liquid phases. Below Te they are fully crystalline; above Te they are partially molten. The freeze stage must bring the product below Te to ensure complete crystallisation before drying begins.

Why

The three temperatures characterise fundamentally different properties of the frozen formulation. Tc is an observation of structural failure under the conditions of freeze-drying. Tg’ is a thermodynamic property of the amorphous phase. Te is a phase-transition property of crystalline components. Which temperatures matter for a given formulation depends on its composition: a fully amorphous biologic formulation requires Tc and Tg’; a mixed crystalline-amorphous formulation requires all three.

How is Tc measured, and what does the result tell you?

Answer

Tc is measured by freeze-drying microscopy (FDM). The formulation is placed on a temperature-controlled microscope stage, frozen, and then warmed at a controlled ramp rate – typically 1-2°C per minute – while the frozen matrix is observed directly. Tc is recorded as the onset temperature at which structural collapse first becomes visible: the collapse front advances through the frozen cake as pore walls soften and flow. The result is used directly as the upper temperature limit for primary drying, with a safety margin of 2-3°C applied in practice.

Why

FDM is the only measurement method that directly observes collapse in the frozen matrix under conditions that approximate primary drying. It is specific to the formulation at the concentration tested and accounts for all component interactions. DTA and EIS measure Tg’, which predicts Tc, but FDM confirms it visually. Where a formulation’s Tc is unknown, FDM is the starting point for primary drying design.

When this advice may not apply

Where FDM is not available, Tg’ measured by DTA or EIS can serve as a conservative proxy for Tc – the true Tc is typically a few degrees above Tg’, so using Tg’ as the design limit provides an additional margin of safety. This approach is most reasonable for early-stage screening, where a precise Tc is not yet required. For clinical and commercial development, direct Tc measurement by FDM is the expected standard.

How is Tg’ measured, and how does it relate to Tc?

Answer

Tg’ is measured by differential thermal analysis (DTA), electrical impedance spectroscopy (EIS), or both simultaneously. In DTA, the frozen sample is warmed at a controlled rate; Tg’ appears as a step change in heat flow as the amorphous phase transitions from glassy to rubbery. In EIS, the same transition appears as a step change in electrical impedance. Simultaneous DTA/EIS measures both signals from a single sample in a single run, providing two independent determinations without additional material or time. Tg’ is typically 2-5°C below Tc for the same formulation.

Why

Tg’ and Tc are related but not identical. Tg’ is a thermodynamic property of the amorphous phase; Tc is an observation of structural failure under the specific conditions of freeze-drying microscopy. The offset between them is broadly consistent, which makes Tg’ a useful cross-check and a conservative design boundary when Tc has not been measured directly.

DTA alone gives a weak or ambiguous signal in dilute biologic formulations, where the amorphous fraction is small relative to the ice fraction. EIS detects the same transition through a different physical mechanism – the change in ionic mobility as the amorphous phase softens – and tends to give a clearer signal in these cases. Running both from the same sample removes the ambiguity without requiring a repeat measurement.

What is Te, and when does it matter?

Answer

Te is the eutectic temperature of a crystallising component – the temperature at which that component transitions between fully crystalline and partly molten states. Formulations containing mannitol, glycine, sodium chloride, or potassium dihydrogen phosphate all have a eutectic transition. The freeze stage must take the product below Te to ensure those components fully crystallise. The annealing step – used to promote complete crystallisation – is conducted above Tg’ (to allow molecular mobility) but below Te (to keep crystalline components solid). Te is measured by DTA or EIS as a distinct thermal event on cooling and warming.

Why

Crystallising excipients that have not fully crystallised by the end of the freeze stage remain amorphous. Amorphous mannitol and glycine depress Tg’ and therefore Tc of the formulation as a whole. A cycle designed on the assumption that mannitol is crystalline will produce collapse if annealing is incomplete, because the effective Tc is lower than measured. Knowing Te confirms whether the freeze stage – including temperature, hold time, and cooling rate – was adequate to drive crystallisation to completion.

Te is not the same as Tg’. They can be confused because both are measured by the same instruments and appear as thermal events during warming. Te is a first-order phase transition (latent heat, sharp peak in DTA); Tg’ is a second-order transition (step change in heat capacity, broader signal). In a mixed formulation, both events may appear in the same scan.

Which measurements do you need for your formulation?

Answer

For most biologic formulations, measure Tc by FDM and Tg’ by DTA/EIS. If the DTA signal is weak, add EIS or run both simultaneously. If the formulation contains mannitol, glycine, or inorganic salts, measure Te as well, and confirm annealing conditions are adequate to drive crystallisation below Te before drying begins. If concentration changes are planned during development, re-measure: Tc and Tg’ both shift with concentration, and a measurement at 5 mg/mL does not apply at 50 mg/mL.

Why

Each measurement provides information the others cannot reliably substitute for. FDM shows collapse directly; DTA/EIS measures the thermodynamic transition that precedes it. Neither can confirm whether crystallising excipients have fully crystallised – that requires Te. Doing all three relevant measurements in a single characterisation phase is more efficient than diagnosing failures that trace back to missing data later in development.

When this advice may not apply

For predominantly crystalline small-molecule formulations where no amorphous stabiliser is present, Tc and Tg’ may not be relevant – primary drying is governed by Te rather than collapse temperature. In these cases, confirm that the formulation is fully crystalline by X-ray diffraction or DSC before omitting Tc measurement, and ensure Te has been measured rather than assumed.

How do these measurements feed into cycle design?

Answer

Tc sets the upper limit for product temperature during primary drying. Set shelf temperature and chamber pressure so that product temperature – at the warmest vial position, accounting for radiation from chamber walls – stays at least 2-3°C below Tc throughout the drying stage. Tg’ provides a cross-check: if Tg’ and Tc diverge by more than 5°C, re-examine the measurements before committing to a cycle. Te confirms the freeze stage is complete and that annealing has driven crystallisation to the expected end point before primary drying begins.

Why

These temperatures are design inputs, not safety checks after the fact. A primary drying cycle set without Tc data is either unnecessarily conservative – which lengthens the cycle and reduces batch throughput – or unknowingly aggressive, which risks collapse. The margin between measured Tc and actual product temperature determines both the safety of the cycle and the efficiency it can achieve. More headroom below Tc means the cycle can run at a higher shelf temperature and shorter hold time without risk.

For regulatory submissions, cycle parameters must be justified against formulation characterisation data. Under ICH Q8, the design space for primary drying – the range of shelf temperature and chamber pressure that maintains product temperature below Tc – is built directly from these measurements. Without them, there is no documented scientific basis for the design space.

Frequently asked questions

Do I need to measure Tc and Tg’ separately, or will one do?

Both are useful but they answer different questions. Tc from FDM is a direct observation of collapse during freezing and is the primary input to primary drying cycle design. Tg’ from DTA or EIS confirms the thermal event underlying Tc and is expected in regulatory submissions. If FDM is unavailable, Tg’ provides a conservative proxy – typically 2 to 5 degrees C higher than Tc – but it is not a direct substitute for cycle optimisation.

How long does an FDM measurement take?

Typically a few hours per sample, including the freezing ramp, controlled drying under reduced pressure, and image capture across the temperature range. Multiple formulation variants can be screened in a single day, which makes FDM practical for early-stage candidate selection as well as development characterisation.

My DTA signal is too weak to read Tg’ clearly – what should I do?

Add electrical impedance spectroscopy. EIS is significantly more sensitive than DTA alone for detecting the glass transition in dilute or low-solids systems where the thermal signal is small. Running DTA and EIS simultaneously on the same sample gives two independent detection methods and improves confidence in the assigned Tg’ value.

Do I need to re-measure Tc if I change the protein concentration?

Yes. Tc shifts with formulation composition, and protein concentration is one of the more significant variables. A higher protein load typically depresses Tc, narrowing the margin available for primary drying. Assuming the original Tc still applies after a concentration change is a common source of unexpected collapse at scale.

Heard in the Lab

Related Guides

 

Solutions for
all your CDMO needs

 

✕

Dr. Kevin Ward

DIRECTOR OF R&D

Biopharma Group’s Director of R&D is globally recognised as a lyophilisation expert. Kevin has been in the field since 1993 and joined Biopharma Group in 2000. He’s been involved numerous academic research projects and, together with his team, has worked on over 4,000 projects for customers worldwide. 

Kevin received his PhD for investigations into the freeze-drying of pharmaceutical formulations and drug/vaccine delivery systems. Prior to joining the team, Kevin worked at Pfizer Central Research and as a Research Fellow in vaccine development at Aston University. 

Dr. Ward is an editor and a contributing author of articles and texts on freeze drying, most recent being the Springer book “Lyophilization of Pharmaceuticals and Biologicals”. He is also in demand as a frequent lecturer to many of the leading regulatory agencies and prominent pharma companies. In his spare time, Kevin is part of a small acapella group, who sing at weddings and charity events, who recently performed a concert for Ukraine and raised more than £3000 for medical supplies.

✕

Use this form to register for any of our scheduled training courses. We will contact you to confirm payment details, number of attendees and course choice. For payment methods, please see the “Summary of terms & conditions” below the booking form.

Please note that multiple bookings from the same organisation can qualify for a discount – Contact us for more details.

     
    Invoice Address
    Please select your preferred payment method below. A 3% surcharge will be charged on credit/debit cards.        
    Credit/Debit CardPro-Forma Invoice
     
     
     

    Summary of terms & conditions:
    An invoice will be issued on receipt of booking. Payment must be made in full before the start of the course. Payment by BACS or credit card is possible, please note however, that we cannot accept/process payment by cheque or American Express.

    In the case of card payments, please note that there will be an additional 3% booking fee applied. All card payments are processed in pounds sterling (GBP) at rates that are the prevailing exchange rate on the day.

    We use xe.com to calculate our rates but your card issuer may use a different rate and may also apply additional charges that are beyond our control.

    Cancellation Policy:
    Cancellation in writing more than 5 weeks before the course start date, will incur a service charge deduction of 30% of the applicable fee. No refunds can be made for cancellation after this date. Substitutes will be accepted at any time. Transfer to another scheduled course must be made in writing and a service charge will be incurred.

    Full Ts&Cs available on request.

    UK VAT registration number: GB 945 602 420

    ✕

    David Banks

    HEAD OF TECHNICAL SERVICES - USA

    Now based in California, David is Head of Technical Services at Biopharma Group, having rejoined the group in 2013 as a Senior Scientist following experience as a coordinator in the NHS and various analytical laboratories. David was promoted to the senior management team in 2016, having built up significant experience in the freeze-drying industry, providing analytical research, consultancy, and product and process development for customers worldwide. Since then, David has helped expand Biopharma Group’s technical portfolio, leading the growth of the R&D laboratories and assisting the move into diagnostic and GMP pharma production.

    David particularly enjoyed his leading role in Biopharma Group’s covid production campaign which saw ‘all hands to the deck’ and a large expansion in staff as we developed and manufactured up to 100,000 covid tests per day throughout the pandemic.

    In 2024, David will pivot slightly away from the operational side of the business and take up a more commercial role. This will involve assistance to the Heads of Sales for the various business areas in finding new opportunities for growth.

    Outside of work, David enjoys spending time with his family, and 3 children.

    ✕

    Dr. Edmond Ekenlebie

    R&D MANAGER

    Edmond is the Research & Development Manager at Biopharma. With over a decade of experience in the pharmaceutical industry spanning roles as a Pharmacist, Principal Scientist, and now an R&D manager. Edmond joined the team in 2014 after a PhD from Aston University in Birmingham, UK. His PhD focused on optimising the bulk freeze-drying process and the implications of powder rheology using methods including the novel use of Micro X-ray tomography. He also holds an MSc in Pharmaceutical Science with Management Studies (Distinction) from Kingston University in London. Edmond brings a unique perspective to drug development, leading a team of talented scientists and brings a wealth of expertise in stabilising parenteral, biologics, small molecules and in vitro diagnostics using rigorous research and development. Edmond’s expertise in lyophilisation has proven invaluable to numerous small to large biotech and pharmaceutical companies over the years through consultancy. Beyond the lab coat and boardroom, Edmond has a passion for football and enjoys crafting delectable dishes in the kitchen.

    ✕

    Chelsea Gemmell

    PRODUCTION MANAGER

    Chelsea has 10 years’ experience working in laboratories across both industry and academia settings. She joined Biopharma in 2016 as a Research Assistant in the R&D laboratory and progressed to Senior Scientist, working on thermal analysis characterisation and developing freeze-drying cycles. In 2020 the company expanded its production services for medical devices and Chelsea moved into this department to manage its operations as Production Manager. She has successfully transferred multiple projects into manufacturing developments and helped customers to streamline processes. Alongside this, she is a quality management representative and supports the company with holding its ISO 9001 and ISO 13485 accreditations.

    One of Chelsea’s most memorable projects was freeze-drying goldfish for an art exhibition piece.

    ✕

    Dr. Pranav Bhujbal

    PRINCIPAL SCIENTIST - FORMULATION & ANALYTICAL DEVELOPMENT

    Pranav has almost 10 years of scientific experience in the pharmaceutical industry, and hands-on technical experience. A pharmacist by training, his academic achievements include a Ph.D. in Liposomal Drug delivery from Aston University, an M.Sc. (with Distinction) in Pharmaceutical Sciences from the University of Greenwich and a bachelor’s degree in pharmacy. Prior to joining Biopharma Group, Pranav worked at multi-national pharmaceutical companies, including Aesica Pharmaceuticals Ltd., LM Manufacturing Ltd., Cipla Ltd, Serum Institute Pvt. Ltd. as a Formulation and Early Product Development Scientist, and Pfizer as a part of industrial collaboration.

    He joined Biopharma Group over 5 years ago as a Senior Scientist. In 2023, he earned a promotion, seamlessly transitioning into the position of Principal Scientist. He brings considerable expertise and a versatile skill set to the forefront of dosage form development, tech transfer, scale-up, and validation activities. In his current role at Biopharma, he has emerged as a specialist in lyophilisation, providing valuable consultancy support to meet the diverse needs of existing and new clients. Throughout his professional journey, he has acquired in-depth expertise in Pre-formulation studies, Process design and Quality-by-design (QbD) concepts. He is recognised for his adept interpersonal skills, effective leadership, and ability to foster inclusive and supportive work environments. Beyond his professional pursuits, he indulges in his passions for travel, culinary exploration, and dancing during his leisure time.

    ✕

    Dr. Bhaskar Pandya

    SENIOR SCIENTIST

    Bhaskar joined Biopharma Group in 2021 as a Senior Scientist after a PhD from De Montfort University in Leicester, UK. Working with Professor Geoff Smith, his PhD was centred on the single vial monitoring of the freeze drying process using through vial impedance spectroscopy (TVIS). At Biopharma Process Systems in Winchester, Bhaskar is managing several highly collaborative projects for clients in the pharma and diagnostics sectors involving product and process assessments, formulation development, lyophilization cycle development, post process analyses, packaging and consultancy for new and existing products.

    Bhaskar holds a BSc (Hons) in Pharmaceutical and Cosmetic Science with a sandwich industrial placement within product development of Zydis® ODT at Catalent in Swindon, UK. He also holds a master’s by Research (MRes) from University College London, where his research involved exploring the paediatric application of hot melt extrusion and cyclodextrins for reformulating a poorly soluble active ingredient.

    Bhaskar has been playing the ‘Tabla’, an Indian percussionist instrument since childhood and loves to jam! He is also a Cricket enthusiast and dreams to play in the World Cup after retiring!

    ✕

    Andrew Cowen

    CHAIRMAN

    Andrew is the Chairman of the PE487 Group which is the ultimate owner of the divisions that make up Biopharma Group. Andrew led the purchase of the original freeze dryers division (Biopharma Process Systems) in 2009 when he, and three private shareholders bought the company and started the process of development that has taken Biopharma Group to where it is now. 

    Andrew is not a scientist but has applied his experience in a variety of businesses to protein stabilisation and its associated processes, and products. Andrew also chairs an automotive component group and is a director and trustee of a scientific prize fund. 

    Outside of his business interests Andrew has a small farm where he runs a flock of sheep.

    ✕

    Dr. Roberto Castangia

    GROUP SALES DIRECTOR

    With over twenty years of experience spanning biopharma, biotech, and food industries, Roberto leads as Group Sales Director the commercial side of PE487, overseeing the diverse group of companies that fall under the Biopharma Group umbrella to provide innovative solutions for the life sciences and healthcare sectors. Holding a PhD in Chemical Biology, he bridges his scientific background with business experience to develop and execute global strategies, services, and development of new products.

    Outside his business interests, Roberto does coaching, sports and enjoys his love for the sea travelling back to Sardinia. 

    ✕

    Andrew Howells

    GROUP OPERATIONS DIRECTOR

    A degree in Electronic Engineering and a commercial MSc led to 20 years as MD of several large organisations, much of it in supplying the food, pharma, and cleanroom sectors with equipment and services. For the last 7 years, Andrew has been as Group Operations Director at Biopharma Group with responsibility for service, R&D, laboratory and GMP operations, as well as the operations of our other acquisitions.

    Andrew is a great believer in “get it right first time”. At Biopharma Group, we have the ability to make decisions and act quickly to get things done, do it once and do it right.

    ✕


    Use this form to register your interest in our future scheduled training courses. 

       
       
       
       
       
      ✕

      Niloofar Ganji

       RESEARCH SCIENTIST

      Niloofar, aka Niloo, joined Biopharma Group as a Research Scientist in 2020, becoming Senior Scientist in 2024. She has a wealth of expertise in molecular biology techniques and lyophilization as well as extensive experience in managing diverse projects, formulating products, and equipment validation. Niloo’s educational background includes a MSc in Genomic Medicine and a BSc in Molecular and Cellular Biology (Genetics).

      The core of her role is developing understanding of client's requirements ahead of project commencement, creating strategies, and executing projects aimed at meeting those needs. It involves sharing our expertise with the customer in areas such as formulation development, freeze-drying cycle development, process improvement and stability assessments. This allows us to help our clients complete their product development efficiently to a high standard, while ensuring they are delivered on time and within budget.

      Outside of work, Niloo enjoys skiing and surfing.

      ✕

      Mervyn Middleton

      SENIOR SCIENTIST

      Mervyn holds a BSc (hons) Biochemistry Degree from the University of Portsmouth. After graduating in July 2009, Mervyn joined Biopharma in December 2009, where he worked for six years to 2015. During this time, Mervyn gained significant experience of product analysis and freeze-drying cycle development/optimisation. Following this, Mervyn joined the Bio Products Laboratory (BPL), where he worked within a production setting, gaining considerable experience of the operations of production freeze-dryers and the management of GMP cleanroom environments. During his time at BPL, Mervyn also attained a master’s degree in Biopharmaceuticals from King’s College London, having conducted a research project within the R&D department at BPL which focused on the impact of viricidal heat treatment processes on Factor VIII/ vWF concentrates.

      Mervyn returned to Biopharma Group as a Senior Scientist in February 2021 and has since worked on approximately 55+ customer projects involving a range of activities, including characterisation of both pre-lyophilised and lyophilised products, formulation development, freeze-drying cycle development and optimisation, process auditing and consultancy on all stages of the freeze-drying development and scale-up process. Additionally, Mervyn is a contributor to the freeze-drying courses provided by Biopharma, during which he delivers lectures and provides hands-on training with the freeze-drying equipment and analytical instruments associated with product characterisation.

      Mervyn lives by the seaside with his wife, three young children and three small dogs. Together they love doing lots of seaside related activities, including walks along the beach, kayaking and paddleboarding.

      ✕
      ✕

      Use this form to contact us and discuss the results of our ROI calculator

        Area of Interest* How did you hear about us?*  
        I am happy to be contacted via:PhoneEmail
         
        ✕

        Sam Woodyard

         RESEARCH SCIENTIST

        Sam started at Biopharma Group after graduating from Reading University with a degree in Biological Sciences, focusing on molecular biology and biochemistry. Following this, Sam completed an additional research project in the cardiovascular laboratory at Reading, examining protein expression/inhibition in murine red blood cells. 

        Sam started at Biopharma in 2020 as a Research Assistant in the R&D department and progressed to Research Scientist in 2022 where his main responsibilities include project management, customer communication, freeze-drying formulation and cycle recipe development and performing pre/post lyo analysis. Since joining Biopharma, Sam has worked on a wide range of pharmaceutical and diagnostic projects, including drug product and drug substance, collagen scaffold and lipid nanoparticle development, as well as IVD assay design and development, including the design of IVDR-compliant assays in Lyobead format ranging from drug detection sprays to PCR mastermixes.

        Sam loves to travel and enjoys the opportunity to visit customer sites to perform training courses and consultancy in person.